Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Tirzepatide Explained: Research, Evidence & Dosage Guide

Tirzepatide Explained: Research, Evidence & Dosage Guide

Jun 11, 2026 4 min GLP-1 / Metabolic
TL;DR
Tirzepatide is a dual-hormone agonist studied for blood sugar control and weight loss. Clinical trials show it outperforms older drugs on both fronts. Research is now exploring its effects on sleep apnea, fatty liver disease, and heart failure.

What Is Tirzepatide?

Tirzepatide is a synthetic peptide given as a once-weekly injection under the skin. Its nickname in research circles is a dual incretin agonist. That's a mouthful — here's what it means.

Your gut makes two hormones after you eat: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both tell the pancreas to release insulin, slow digestion, and signal the brain that you're full. Most older drugs in this class only copy GLP-1. Tirzepatide copies both.[2] That double action is why researchers got excited.

What Is Research Studying It For?

1. Type 2 Diabetes

The biggest body of evidence is in people with type 2 diabetes. A key measure doctors use is HbA1c — a blood test that shows average blood sugar over roughly three months. Lower is better. In the landmark SURPASS-1 phase 3 trial, tirzepatide cut HbA1c by up to 2.07 percentage points compared to placebo, with a large share of participants reaching normal blood sugar ranges.[5]

A separate review comparing tirzepatide head-to-head against semaglutide (a popular GLP-1-only drug) found tirzepatide produced greater reductions in both HbA1c and body weight across multiple randomised trials.[6]

Researchers also tested it on top of existing insulin therapy. In the SURPASS-5 trial, adding tirzepatide to insulin glargine dropped HbA1c by up to 2.40 percentage points — versus just 0.86 points for placebo — and participants lost up to 8.8 kg in body weight over 40 weeks.[3]

2. Weight Loss and Obesity

Weight loss has become one of the most-watched areas of tirzepatide research. The SURMOUNT programme — a global set of phase 3 trials — showed many participants achieving 20% or more body weight reduction.[1] That's a level previously only seen with bariatric surgery in research settings.

A large real-world study published in JAMA Internal Medicine compared over 18,000 patients taking either tirzepatide or semaglutide. People on tirzepatide were 3.24 times more likely to lose 15% or more of their body weight, and the gap kept widening out to 12 months — with similar rates of side effects between the two drugs.[4]

3. Other Obesity-Related Conditions

Because excess weight affects so many body systems, researchers are studying tirzepatide's impact beyond blood sugar and the scale. Current and recent trials are examining:

  • Sleep apnea — the SURMOUNT-OSA study looks at whether weight loss from tirzepatide reduces breathing interruptions during sleep[1]
  • Fatty liver disease (called MASH — metabolic-dysfunction associated steatohepatitis) — the phase 2 SYNERGY-NASH trial is investigating liver health improvements[1]
  • Heart failure with preserved ejection fraction — the SUMMIT trial is exploring whether tirzepatide helps a type of heart failure common in people with obesity[1]

What Does the Evidence Show So Far?

Across the SURPASS trials, tirzepatide at approved doses (5 mg, 10 mg, and 15 mg weekly) beat older diabetes drugs — including semaglutide 1 mg and insulin — on blood sugar control and weight loss.[2] That combination is unusual; many diabetes drugs cause weight gain.

Side effects? The most common are nausea, diarrhoea, decreased appetite, and vomiting. These are mostly mild to moderate and tend to fade over time. They match the profile seen with GLP-1 drugs as a class.[2] The risk of dangerously low blood sugar (hypoglycaemia) was low when tirzepatide was used without insulin.[5]

Experts note that long-term cardiovascular outcome data is still being gathered, and ongoing trials will fill those gaps.[1]

Dosing: What the Research Used

Trials consistently started participants at a low dose — 2.5 mg per week — and stepped up by 2.5 mg every four weeks until reaching the target dose of 5 mg, 10 mg, or 15 mg.[3] This gradual ramp-up is designed to reduce stomach side effects. Want to see how the studied doses break down? Check the full tirzepatide dosage chart, and use our calculator to explore research dose ranges.

This article is for educational and research purposes only. It is not medical advice. Always consult a qualified healthcare professional before making any health decisions.

Sources

  1. Tirzepatide for overweight and obesity management. — Expert opinion on pharmacotherapy, 2025. PMID 39632534.
  2. Tirzepatide: A Review in Type 2 Diabetes. — Drugs, 2024. PMID 38388874.
  3. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. — JAMA, 2022. PMID 35133415.
  4. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. — JAMA internal medicine, 2024. PMID 38976257.
  5. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. — Lancet (London, England), 2021. PMID 34186022.
  6. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. — Diabetologia, 2024. PMID 38613667.
See the dosage chart — Tirzepatide
A dual incretin agonist researched for glycemic control and weight.
Tirzepatide

FAQ

What makes tirzepatide different from semaglutide?
Semaglutide targets only the GLP-1 hormone receptor. Tirzepatide targets both GLP-1 and GIP receptors at the same time. Research suggests this dual action produces greater reductions in blood sugar and body weight. A large real-world study found tirzepatide users were over three times more likely to lose 15% of their body weight compared to semaglutide users.[4]
What doses were used in tirzepatide clinical trials?
Phase 3 trials used three maintenance doses: 5 mg, 10 mg, and 15 mg, all injected once weekly under the skin. Participants always started at 2.5 mg and increased gradually every four weeks to minimise nausea and other gut side effects. You can explore these dose levels on the tirzepatide dosage chart and calculator.[3]
What are the most common side effects seen in research?
The most frequently reported side effects across trials are nausea, diarrhoea, vomiting, and decreased appetite. These are generally mild to moderate and tend to improve as the body adjusts. They are consistent with the side effect profile of the broader GLP-1 receptor agonist drug class. Serious hypoglycaemia was rare when tirzepatide was used without insulin.[2]
Is tirzepatide only being studied for diabetes and weight loss?
No. While diabetes and obesity are the most studied areas, researchers are actively investigating tirzepatide's effects on sleep apnea, fatty liver disease (MASH), and a type of heart failure common in people with obesity. Early results in these areas look promising, but more data from ongoing trials is still needed.[1]
For research and educational use only. Not medical advice.